Given that CBDA is anticonvulsant in the Scn1a+/− mouse model of Dravet syndrome, the present results suggest CBDA might contribute to the anticonvulsant effects of orally administered artisanal cannabis extracts24. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.